MHLW (Japan) approval for Phesgo, the fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast and colorectal cancer – Chugai
Chugai Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for Phesgo combination for Subcutaneous Injection MA, IN… read more.